Mounjaro Vs. Trulicity: Drug Comparison

Mounjaro^® (tirzepatide) is an injectable medication used to treat type 2 diabetes by improving blood sugar control and promoting weight loss. It functions by activating two receptors, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which enhance insulin secretion and slow gastric emptying. Mounjaro is administered once weekly, with dose adjustments made based on the patient's response. Common side effects include nausea, diarrhea, and decreased appetite. It should be used with caution in individuals with a history of thyroid cancer or multiple endocrine neoplasia syndrome type 2​.

Trulicity^® (dulaglutide) is an injectable medication used to improve blood sugar control in adults and pediatric patients aged 10 years and older with type 2 diabetes, alongside diet and exercise. It acts as a glucagon-like peptide-1 (GLP-1) receptor agonist, enhancing insulin secretion, slowing gastric emptying, and reducing glucagon production. Additionally, Trulicity is indicated to reduce the risk of major adverse cardiovascular events, such as heart attack, stroke, and cardiovascular death in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. Administered once weekly, Trulicity can be used alone or with other diabetes medications. Common side effects include gastrointestinal issues like nausea, diarrhea, and vomiting. It should be used cautiously in individuals with a history of pancreatitis​.

Glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist

Glucagon-like peptide-1 (GLP-1) receptor agonist

Mounjaro (tirzepatide) is indicated:

• As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Trulicity (dulaglutide) is indicated:

• As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.

• To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors

• Typically taken as an injection once weekly

• Comes in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.5 mL single-dose pens or single-dose vials

• Typically taken as an injection once weekly

• Comes in 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg per 0.5 mL single-dose pens

The most common adverse reactions, reported in ≥5% of patients treated with Mounjaro are:

• Nausea

• Diarrhea

• Decreased appetite

• Vomiting

• Constipation

• Indigestion

• Abdominal pain

Most common adverse reactions (incidence ≥5%) are:

• Nausea

• Diarrhea

• Vomiting

• Abdominal pain

• Decreased appetite

• Personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome type 2

• Known serious hypersensitivity to tirzepatide or any of the excipients in Mounjaro

• Drug interactions: Mounjaro delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications

• Patients with a personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome type 2

• Patients with a serious hypersensitivity reaction to dulaglutide or any of the product components

• Drug interactions: Trulicity delays gastric emptying and has the potential to reduce the rate of absorption of concomitantly administered oral medications

• Pancreatitis

• Low blood sugar with concomitant use of insulin secretagogues or insulin

• Hypersensitivity reactions

• Acute kidney injury

• Severe gastrointestinal disease

• Diabetic retinopathy complications in patients with a history of diabetic retinopathy

• Acute gallbladder disease

• Pregnancy: Based on animal study, may cause fetal harm

• Females of reproductive potential: Females using oral contraceptives should consider switching to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation

• Thyroid C-cell tumors

• Pancreatitis

• Low blood sugar: Concomitant use with an insulin secretagogue or insulin may increase the risk of low blood sugar, including severe low blood sugar

• Hypersensitivity reactions

• Acute kidney injury

• Severe gastrointestinal disease

• Diabetic retinopathy complications

• Acute gallbladder disease

• Pregnancy: Should be used during pregnancy only if the potential benefit justifies the potential risk to fetus

WARNING: RISK OF THYROID C-CELL TUMORS

Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.

Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.

WARNING: RISK OF THYROID C-CELL TUMORS

Dulaglutide causes thyroid C-cell tumors in rats. It is unknown whether Trulicity causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined.

Trulicity is contraindicated in patients with a personal or family history of MTC and in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.

*This information is from the label for brand name Mounjaro. See the Full Prescribing Information for more complete information. Tirzepatide, the active ingredient in Mounjaro, may also be the active ingredient in other medications, and this information may not be accurate for all medications that include the active ingredient tirzepatide.

*This information is from the label for brand name Trulicity^®. See the Full Prescribing Information for more complete information.